Inovio Pharmaceuticals and the Parker Institute for Cancer Immunotherapy Establish Clinical Development Collaboration To Evaluate ...
Advances development of Inovio’s ASPIRE™ (Antigen SPecific Immune REsponses) immunotherapy platform as a foundation for novel combination regimen approaches Engages the Parker Institute’s extensive immunotherapy expertise and academic and research network …